Official Journal
of the European Union

EN
L series

2025/2344

20.11.2025

COMMISSION IMPLEMENTING DECISION (EU) 2025/2344

of 19 November 2025

repealing Implementing Decision (EU) 2024/2930 postponing the expiry date of the approval of dazomet for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products ([1]), and in particular Article 14(5) thereof,

After consulting the Standing Committee on Biocidal Products,

Whereas:

(1) Dazomet was included in Annex I to Directive 98/8/EC of the European Parliament and of the Council ([2]) as an active substance for use in biocidal products of product-type 8. Pursuant to Article 86 of Regulation (EU) No 528/2012, it was therefore considered approved until 31 July 2022 under that Regulation subject to the conditions set out in Annex I to Directive 98/8/EC.

(2) On 26 January 2021, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of the approval of dazomet for use in biocidal products of product-type 8 ('the application'). The application was evaluated by the competent authority of Belgium.

(3) Pursuant to Commission Implementing Decision (EU) 2021/1289 ([3]), the expiry date of approval of dazomet for use in biocidal products of product-type 8 was postponed to 31 January 2025. That expiry date was further postponed to 31 July 2026 by Commission Implementing Decision (EU) 2024/2930 ([4]) in order to allow sufficient time for the examination of the application.

(4) Commission Implementing Regulation (EU) 2025/2345 ([5]) renewed the approval of dazomet for use in biocidal products of product-type 8, subject to the conditions in the Annex to that Regulation, including the expiry date of approval. Therefore, it is appropriate to repeal Implementing Decision (EU) 2024/2930 postponing the expiry date of the approval of dazomet,

([1]) OJ L 167, 27.6.2012, p. 1, ELI: http://data.europa.eu/eli/reg/2012/528/oj.
([2]) Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market (OJ L 123, 24.4.1998, p. 1, ELI: http://data.europa.eu/eli/dir/1998/8/oj).
([3]) Commission Implementing Decision (EU) 2021/1289 of 2 August 2021 postponing the expiry date of approval of dazomet for use in biocidal products of product-type 8 (OJ L 279, 3.8.2021, p. 45, ELI: http://data.europa.eu/eli/dec_impl/2021/1289/oj).
([4]) Commission Implementing Decision (EU) 2024/2930 of 28 November 2024 postponing the expiry date of the approval of dazomet for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L, 2024/2930, 2.12.2024; ELI: http://data.europa.eu/eli/dec_impl/2024/2930/oj).
([5]) Commission Implementing Regulation (EU) 2025/2345 of 19 November 2025 renewing the approval of dazomet as an active substance for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L, 2025/2345, 20.11.2025, ELI: http://data.europa.eu/eli/reg_impl/2025/2345/oj).

HAS ADOPTED THIS DECISION:

Article 1

Implementing Decision (EU) 2024/2930 is repealed.

Article 2

This Decision shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

Done at Brussels, 19 November 2025.

For the Commission
The President
Ursula VON DER LEYEN